![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
ABX464 decreases total HIV DNA in PBMC's when administered during 28 days to HIV-infected patients who are virologically suppressed
|
|
|
Authors
R. Paredes1, L. Vandekerckhove2, B. Clotet1, M. Moutchen3, S. De Wit4, D. Podzamczer5, L. Cotte6, J. Reynes7, P. Gineste8, H. Ehrlich8, J.-M. Steens8
1Infectious Diseases & irsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, 2HIV Cure Center Internal Medicine and Infectious Diseases Ghent University Hospital, Ghent, Belgium, 3Medecine Interne/infectiologie CHU Sart Tilman, Liege, Belgium, 4C.H.U. Saint-Pierre, Brussels, Belgium, 5Hospital Universitari de Bellvitge, Barcelona, Spain, 6Hopital de la Croix Rousse, Lyon, France, 7Hopital Gui de Chauliac, Montpellier, France, 8ABIVAX, Paris, France
![IAS1](../images/072817/072817-3/IAS1.gif)
![IAS2](../images/072817/072817-3/IAS2.gif)
![IAS3](../images/072817/072817-3/IAS3.gif)
![IAS4](../images/072817/072817-3/IAS4.gif)
![IAS5](../images/072817/072817-3/IAS5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|